![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves J&J's Remicade to Treat Psoriatic Arthritis
FDA Approves J&J's Remicade to Treat Psoriatic Arthritis
May 23, 2005
The FDA has approved Centocor's Remicade (infliximab) as a treatment for active psoriatic arthritis, the ninth indication the agency has granted for the drug.
The FDA describes infliximab as a monoclonal antibody that works by blocking the overproduction of an immune system protein, an underlying cause of these inflammatory diseases.
First approved in 1998 as a treatment for Crohn's disease, Remicade is also indicated to treat rheumatoid arthritis and ankylosing spondylitis. Centocor is a unit of Johnson & Johnson.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct